Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer known as Gastrointestinal Stromal Tumors (GIST). The study is comparing the effectiveness and safety of a new treatment called DCC-2618 with an existing medication named Sunitinib. Patients participating in this study have previously been treated with another medication called Imatinib.

The purpose of the study is to evaluate how well DCC-2618 works in patients with advanced GIST who have already received treatment with Imatinib. During the study, participants will be randomly assigned to receive either DCC-2618 or Sunitinib. The study will monitor the progression of the disease and any side effects experienced by the participants. The treatment will be administered orally, meaning it will be taken by mouth in the form of capsules or tablets.

This study aims to provide valuable information about the potential benefits and risks of using DCC-2618 as a treatment option for patients with advanced GIST. The results will help determine if DCC-2618 can be a more effective treatment compared to Sunitinib for patients who have already been treated with Imatinib.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, diagnosis of gastrointestinal stromal tumors (GIST), and previous treatment with imatinib.

    A tumor tissue sample is required for mutation status confirmation. If an archival sample is unavailable, a fresh biopsy is necessary.

  2. Step 2

    Randomization

    Eligible participants are randomly assigned to receive either sunitinib or ripretinib (DCC-2618).

    Randomization ensures that each participant has an equal chance of receiving either treatment.

  3. Step 3

    Treatment administration

    Participants receiving sunitinib will take Sunitinib AqVida 12.5 mg capsules orally. The dosage and frequency are determined by the study protocol.

    Participants receiving ripretinib will take QINLOCK 50 mg tablets orally. The dosage and frequency are determined by the study protocol.

  4. Step 4

    Monitoring and assessments

    Regular monitoring is conducted to assess the effectiveness and safety of the treatment. This includes radiologic reviews to evaluate tumor progression.

    Participants undergo various assessments, including vital signs, ECGs, and laboratory tests, to monitor health and detect any adverse effects.

  5. Step 5

    End of treatment

    The treatment continues until the study's estimated end date or until the participant experiences unacceptable side effects or disease progression.

    Upon completion, a final assessment is conducted to evaluate the overall response to the treatment.

Who can join the trial?

6 criteria

  • Patients must be **18 years or older** at the time they agree to participate in the study.
  • Patients must have a **histologic diagnosis** of gastrointestinal stromal tumors (GIST). This means that a sample of the tumor has been examined under a microscope to confirm the type of cancer.
  • Patients need to provide a **tumor tissue sample** from a previous biopsy. If this is not available, a new biopsy may be required.
  • A **molecular pathology report** showing the mutation status of specific genes called **KIT/PDGFRA** must be available. This report helps to understand the genetic changes in the tumor. If the report is not available, a tissue sample or new biopsy is needed to confirm this information.
  • Patients must have either **progressed on imatinib** (a medication previously used) or have a documented intolerance to it. This means the cancer has worsened despite treatment, or the patient cannot tolerate the medication. Imatinib treatment should be stopped at least **10 days** before starting the study medication.
  • Patients must have an **ECOG performance status** of **2 or less** at screening. This is a scale used to assess how well a patient can perform daily activities, with lower numbers indicating better function.

Who cannot join the trial?

4 criteria

  • Patients who have not received first-line therapy with imatinib cannot participate.
  • Patients who do not have advanced gastrointestinal stromal tumors are excluded.
  • Patients who are not within the specified age range for the study cannot join.
  • Patients who are part of a vulnerable population may be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • DCC-2618

    is an investigational medication being studied for its effectiveness in treating advanced gastrointestinal stromal tumors (GIST). It is being compared to another treatment to see how well it works in patients who have already received initial treatment with another medication.

  • Sunitinib

    is a medication used to treat certain types of cancer, including advanced gastrointestinal stromal tumors. In this study, it is being used as a comparison to evaluate the effectiveness of the investigational medication DCC-2618.

  • Imatinib

    is a medication that is commonly used as the first-line treatment for gastrointestinal stromal tumors. Patients in this study have previously been treated with imatinib before participating in the trial.

What is already known about the treatment

  • DCC-2618

    This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating advanced gastrointestinal stromal tumors (GIST) after initial treatment with imatinib. It is in the investigational stage and is not yet widely available in medical practice. The main therapeutic indication is for patients with GIST who have not responded to first-line treatment. DCC-2618 works by inhibiting specific enzymes that promote tumor growth, thereby slowing down or stopping the progression of the disease. It is classified as a tyrosine kinase inhibitor, which targets specific proteins involved in cancer cell growth.

  • Sunitinib

    This medication is taken orally and is approved for use in treating various types of cancer, including advanced gastrointestinal stromal tumors (GIST) after treatment with imatinib. It is well-documented in medical literature and is commonly used in clinical practice. The primary therapeutic indication is for patients with GIST who have not responded to initial therapy. Sunitinib functions by blocking multiple enzymes that contribute to cancer cell growth and blood vessel formation, effectively inhibiting tumor progression. It belongs to the pharmacological class of tyrosine kinase inhibitors, targeting multiple pathways involved in cancer development.

Investigated diseases

Gastrointestinal Stromal Tumors – Gastrointestinal stromal tumors (GIST) are a type of tumor that occurs in the digestive tract, most commonly in the stomach or small intestine. They originate from special cells in the wall of the gastrointestinal tract known as interstitial cells of Cajal. These tumors can vary in size and may grow slowly or more rapidly, depending on various factors. As they progress, they can cause symptoms such as abdominal pain, bleeding, or a feeling of fullness. GISTs are often characterized by mutations in specific genes, which can influence their behavior and response to treatment. They are considered a rare type of cancer, and their progression can be monitored through imaging and other assessments.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-513277-52-00Protocol codeDCC-2618-03-002Estimated enrolment384 patientsSponsorDeciphera Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.